RealFeedApp Type 1 diabetes: new insulin formula for the liver
Diasome is preparing to launch Phase III clinical trials for its HDV-based insulin, designed to target hepatocytes via the portal vein.
- Field
- gene therapy
- What they did
- Diasome is developing a new insulin formulation delivered to liver cells using lipid nanoparticles to target glucose and fat metabolism.
- Why it matters
- This could help treat type 1 diabetes, as current methods do not use drugs effective for type 2 diabetes, and there is an unmet need for new solutions.
#type 1 diabetes#insulin#clinical trial#hepatocytes#lipid nanoparticle
